GERON CORP Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
GERON CORP (GERN) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $583.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-02
- GERON CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $583.00K, a 18.02% increase from fiscal 2024.
- GERON CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $494.00K.
- GERON CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2019 was $40.00K, a 60.00% decline from fiscal 2018.
- GERON CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2018 was $100.00K.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $583.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $494.00K 10-K · filed 2025-02-27 |
| 2019-12-31 | $40.00K 10-K · filed 2020-03-12 |
| 2018-12-31 | $100.00K 10-K · filed 2019-03-07 |
| 2016-12-31 | $7.50M 10-K · filed 2017-03-01 |
| 2012-12-31 | $100.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |